Literature DB >> 2446736

Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance.

C Rozman1, E Montserrat, N Viñolas.   

Abstract

To investigate the prognostic significance of gammaglobulin and immunoglobulin levels in chronic lymphocytic leukemia (CLL), survival studies were performed in a series of patients with that disorder. The survival probability of patients with initial levels of gammaglobulin of less than 700 mg/dl was significantly lower (P = 0.03) than in patients with initial levels of 700 mg/dl or more. Decreased initial levels of IgG and IgA also were associated with reduced survival probability (P = 0.027 and P = 0.014, respectively), whereas hypo-IgM did not show any influence on survival. When the influence on survival of gammaglobulin and immunoglobulin concentration was analyzed by Cox's multivariate model, the only variable which entered the regression at significant level was IgA (P = 0.006). As shown by the same type of analysis, the prognostic value of hypo-IgA is independent from the clinical staging. The natural history of hypogammaglobulinemia and hypoimmunoglobulinemia was investigated by sequential analysis in a series of untreated patients. The appearance of decreased levels of these globulins was found to be a continuous process developing spontaneously during the untreated course of the disease. Among factors associated with the appearance of hypogammaglobulinemia during the evolution of CLL, initial lower levels of IgG and IgA, but not IgM, were found in a multivariate analysis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2446736     DOI: 10.1002/1097-0142(19880115)61:2<279::aid-cncr2820610215>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  31 in total

Review 1.  Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma.

Authors:  A Winkelstein; P S Jordan
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

2.  Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.

Authors:  Sameer A Parikh; Jose F Leis; Kari G Chaffee; Timothy G Call; Curtis A Hanson; Wei Ding; Asher A Chanan-Khan; Deborah Bowen; Michael Conte; Susan Schwager; Susan L Slager; Daniel L Van Dyke; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Journal:  Cancer       Date:  2015-04-30       Impact factor: 6.860

3.  IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.

Authors:  D Rizzo; J Chauzeix; F Trimoreau; J B Woillard; F Genevieve; A Bouvier; J Labrousse; C Poli; E Guerin; N Dmytruk; L Remenieras; J Feuillard; N Gachard
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

4.  and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study.

Authors:  Michael Asger Andersen; Casper Tabassum Eriksen; Christian Brieghel; Jorne Lionel Biccler; Caspar da Cunha-Bang; Marie Helleberg; Carsten Utoft Niemann
Journal:  Haematologica       Date:  2018-03-08       Impact factor: 9.941

5.  IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia.

Authors:  Ganchimeg Ishdorj; Erin Streu; Pascal Lambert; Harbhajan S Dhaliwal; Salaheddin M Mahmud; Spencer B Gibson; Versha Banerji; Aaron J Marshall; James B Johnston
Journal:  Blood Adv       Date:  2019-07-23

6.  Reduced IL-4 and interferon-gamma (IFN-gamma) expression by CD4 T cells in patients with chronic lymphocytic leukaemia.

Authors:  S J Hill; S H Peters; M J Ayliffe; J Merceica; A S Bansal
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

7.  Intravenous immune globulin in chronic lymphocytic leukaemia.

Authors:  H Gamm; C Huber; H Chapel; M Lee; F Ries; M A Dicato
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Authors:  Rosa Lapalombella; Leslie Andritsos; Qing Liu; Sarah E May; Rebekah Browning; Lan V Pham; Kristie A Blum; William Blum; Asha Ramanunni; Chelsey A Raymond; Lisa L Smith; Amy Lehman; Xiaokui Mo; David Jarjoura; Ching-Shih Chen; Richard Ford; Christoph Rader; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

Review 9.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

10.  Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia.

Authors:  Doru T Alexandrescu; Peter H Wiernik
Journal:  Med Oncol       Date:  2008-01-05       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.